Blood
Articles in this Issue
First-in-human evaluation of IL2RG blockade in patients with severe aplastic anemia that is refractory to or relapsed on immunosuppressive therapy
Abstract Background: Aplastic anemia (AA) is considered a T cell-mediated autoimmune disease where hematopoietic stem and progenitor cells a...
Trials in progress: Design of a registrational Phase 2 trial (ALLOHA) using an external control arm for TSC-101 for prevention of relapse post allogeneic HCT in patients with ALL, AML, or MDS
Abstract ALLOHA™ (NCT05473910) is a multi-center, Phase 1/2 study evaluating the safety and efficacy of TSC-101 to prevent relapse in HLA-A*...
Prognostic significance of 1q21 gain/amplification and co-existing cytogenetic abnormalities in Chinese patients with newly diagnosed multiple myeloma
Abstract Background: Chromosome 1q21 copy number gain (1q21+) has been identified as an independent adverse prognostic factor in newly diagn...
Acalabrutinib monotherapy versus acalabrutinib plus obinutuzumab combination therapy in treatment-naïve chronic lymphocytic leukemia: A ‘real-world’ study of efficacy and safety at a tertiary academic medical center
Abstract Background Acalabrutinib is currently approved for use as a single agent or in combination with obinutuzumab in patients with previ...
Subclinical neurovascular injury and cognitive outcomes in adults with sickle cell disease: Prevalence and imaging correlates
Abstract Background Silent cerebral infarcts (SCI) are well-known risk factors for stroke and cognitive impairment in ch...
Successful treatment of two refractory acute lymphoblastic leukemia cases with an orelabrutinib-based regimen
Abstract Background The traditional treatment strategy for B-cell acute lymphoblastic leukemia (B-ALL) primarily relies on chemotherapy, but...
The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results
Abstract Background: Hepcidin dysregulation contributes to anemia of chronic inflammation observed in several malignancies, and hepcidin lev...
Targeting p300-mediated histone acetylation inhibits neutrophilic proteinase 3 and prevents the development of sickle chronic kidney disease
Abstract Chronic kidney disease (CKD) is a prevalent condition among sickle cell disease (SCD) patients and serves as a strong predictor of...
Quantitative ex vivo synergy profiling uncovers heterogeneous combination responses in AML primary samples
Abstract Combination chemotherapy is a cornerstone of acute myeloid leukemia (AML) treatment, yet there remains a lack of patient-specific d...
RAS G12 and Q61 codon mutations confer distinct disease characteristics in Acute Myeloid Leukemia and exhibit differential response to RAS(ON) inhibitor RMC-7977.
Abstract Background RAS pathway mutations are present in 10-20% of acute myeloid leukemia (AML) cases at diagnosis, and frequently occur as l...
Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
Abstract Introduction: Most adult patients (pts) with r/r B-ALL die due to disease complications, indicating a need for more effective thera...
High rates of deep molecular response (DMR) in patients (pts) with chronic myeloid leukemia in chronic Phase (CML-CP) who have not achieved dmr after ≥1 year of prior imatinib (IMA) in the asciminib (ASC) monotherapy arm of the Phase 2 ASC4MORE study
Abstract Introduction As treatment (tx) for CML is often lifelong, goals include good quality of life (QOL) and tx-free remission (TFR). Amo...
Treatment-associated healthcare utilization in older adults with AML: A retrospective single-center study
Abstract Background: Treating AML in older adults (OA) presents challenges, including elevated disease risk, increased therapy toxicities, a...
Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.
Abstract Background : Talicabtagene autoleucel (Tali-cel), a second-generation, humanized CAR-T cell therapy targeting CD19, was approved in...
Apixaban pharmacokinetics in newly diagnosed multiple myeloma patients treated in the benefit and isasocut clinical trials: The apixabor/mibapix study
Abstract Introduction The use of immunomodulatory drugs (IMiDs)-containing regimens (CD38 MAb +Rd or +VRd) is the standard of care (SOC) in...
Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up
Abstract Introduction: Patients (pts) with soft tissue plasmacytomas noncontiguous with bone (true extramedullary disease [EMD]) have poor o...
Enhanced efficacy and safety of optimized tandem CD19/CD20 CAR T-cell Therapy in refractory/relapsed B-cell lymphoma
Abstract Background Relapse after CD19-directed CAR T-cell therapy remains a challenge in relapsed/refractory (r/r) B-cell lymphoma (BCL). W...
Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Abstract Background Rocbrutinib, a highly selective, 4th-generation Bruton's tyrosine kinase (BTK) inhibitor, uniquely takes advantages of bo...
Pre-treatment with carfilzomib significantly improves response in R/R MM patients undergoing BCMA-directed CAR T cell therapy
Abstract Introduction: T cell-based immunotherapies (TCI) such as chimeric antigen receptor T cells (CAR T) and T cell engagers (TCEs) have...
Analysis of lymphoma subtypes, involved sites, and treatment outcomes in primary gastrointestinal B-cell lymphomas: A subset analysis within the PELÉ study of brazilian centers.
Abstract Introduction: Primary gastrointestinal tract lymphomas (PGITL) are rare but are the most common site of extrano...
Tyro3 is a key regulator of clot retraction mediated by platelet-derived protein S
Abstract Background: Clot retraction is a crucial step in hemostasis that stabilizes the thrombus by consolidating the f...
TGM2 as a novel therapeutic target in venetoclax-resistant AML: Disrupting histone serotonylation-driven mitophagy with nanoparticle-delivered inhibitors
Abstract TGM2 as a Novel Therapeutic Target in Venetoclax-Resistant AML: Disrupting Histone Serotonylation-Driven Mitophagy with Nanoparticl...
Allogeneic hematopoietic stem cell transplantation for transfusion-dependent pyruvate kinase deficiency in Chinese children: A multicenter retrospective study
Abstract Background Pyruvate kinase deficiency (PKD) is a rare hereditary hemolytic anemia caused by PKLR gene mutations that disrupt erythr...
KarMMa-3 subgroup analysis in older patients with relapsed/refractory multiple myeloma treated with idecabtagene vicleucel
Abstract Introduction: Chimeric antigen receptor (CAR) T-cell therapies are an effective treatment option for patients w...
The KMT2A-PTD oncoprotein depends on ENL but not menin to drive AML gene expression
Abstract Background: Partial tandem duplications of the histone methyltransferase KMT2Agene(KMT2A-PTD) are the most common KMT2A-aberration...